Versant Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-197
| Closed | -$26K | – | 2760 |
|
|
2025
Q1 | $26K | Buy |
197
+61
| +45% | +$7.6K | ﹤0.01% | 1198 |
|
|
2024
Q4 | $11.4K | Buy |
136
+27
| +25% | +$2.22K | ﹤0.01% | 1329 |
|
|
2024
Q3 | $7.98K | Hold |
109
| – | – | ﹤0.01% | 1132 |
|
|
2024
Q2 | $7.46K | Buy |
109
+89
| +445% | +$6.17K | ﹤0.01% | 1090 |
|
|
2024
Q1 | $1.38K | Hold |
20
| – | – | ﹤0.01% | 1459 |
|
|
2023
Q4 | $1.43K | Buy |
20
+6
| +43% | +$345 | ﹤0.01% | 1404 |
|
|
2023
Q3 | $729 | Sell |
14
-9
| -39% | -$524 | ﹤0.01% | 1618 |
|
|
2023
Q2 | $1.46K | Buy |
23
+9
| +64% | +$561 | ﹤0.01% | 1492 |
|
|
2023
Q1 | $758 | Hold |
14
| – | – | ﹤0.01% | 1511 |
|
|
2022
Q4 | $741 | Hold |
14
| – | – | ﹤0.01% | 1369 |
|
|
2022
Q3 | $1K | Hold |
14
| – | – | ﹤0.01% | 1382 |
|
|
2022
Q2 | $1K | Hold |
14
| – | – | ﹤0.01% | 1389 |
|
|
2022
Q1 | $1K | Hold |
14
| – | – | ﹤0.01% | 1408 |
|
|
2021
Q4 | $1K | Hold |
14
| – | – | ﹤0.01% | 1383 |
|
|
2021
Q3 | $1K | Hold |
14
| – | – | ﹤0.01% | 1399 |
|
|
2021
Q2 | $1K | Hold |
14
| – | – | ﹤0.01% | 1394 |
|
|
2021
Q1 | $0 | Hold |
14
| – | – | ﹤0.01% | 1625 |
|
|
2020
Q4 | $0 | Hold |
14
| – | – | ﹤0.01% | 1567 |
|
|
2020
Q3 | $0 | Hold |
14
| – | – | ﹤0.01% | 1544 |
|
|
2020
Q2 | $0 | Hold |
14
| – | – | ﹤0.01% | 1599 |
|
|
2020
Q1 | $0 | Buy |
+14
| New | +$304 | ﹤0.01% | 1743 |
|
|
2017
Q2 | – | Sell |
-19
| Closed | -$220 | – | 1566 |
|
|
2017
Q1 | $0 | Buy |
+19
| New | +$275 | ﹤0.01% | 1560 |
|
Other funds holding ITCI
Versant Capital Management's ITCI Position: Q2 2025 in Review
Versant Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 197 shares — an estimated $26K sold.
Versant Capital Management first reported a position in ITCI in Q1 2017 and held it in 22 quarters. The position peaked at $26K in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Versant Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Versant Capital Management sold 197 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $26K.
- Versant Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2017 and held it in 22 quarters.
- Versant Capital Management's Intra-Cellular Therapies Inc. position peaked at $26K in Q1 2025.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Versant Capital Management's 13F filing for Q2 2025, filed 7 Jul 2025.